A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- RANDOMIZED · PARALLEL · BASIC SCIENCE · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 26
- Population
- ALL · 65 Years to 85 Years
- Duration
- 2024-08-15 to 2025-04-25
- Intervention
- Mitopure (Urolithin A); Placebo
- Comparator
- Placebo; Mitopure (Urolithin A)
- Outcomes measured
- Change in mitochondrial area between placebo and active treated groups assessed via Electron Microscopy — 8-weeks; Change in mitochondrial cristae density between placebo and active treated groups assessed via Electron Microscopy — 8-…; change between groups on the following: maximal mitochondrial O2 consumption assessed via via respirometry on permeabil…; change between groups in mitochondrial calcium retention capacity measured by mitochondrial permeability transition por…; mitochondrial DNA (mtDNA) over nuclear DNA ratio (mtDNA/nDNA) via qPCR — 8-weeks; Changes in body composition via Dual X-ray Absorptiometry (DXA) scan of total and appendicular lean mass — 8-weeks; Changes in composition via Peripheral quantitative computed tomography (pQCT) of muscle tissue — 8-weeks; Changes in the timed up and go test (time needed to stand from an armchair, walk a distance of 3 meters, turn around an…; Changes in grip strength measured by a hand dynamometer — 8-weeks; Changes in Berg balance test: Participant will be asked to maintain a given position or perform a task — 8-weeks; Changes in distance walked during the six-minute walk test — 8-weeks; Changes in the 30-second stand test: Participant will stand as many times as s/he can from a seated position for 30-sec…; Changes in Four-square step test: To assess balance, participant will step over small sticks placed in an X on the floo…; Changes in Unipedal stance test (UPST): First a ball will be kicked to determine dominant leg, then participant will be…; Recording of adverse events — 8-weeks; Quantification of muscle fiber type (type I/II) via Myosin Heavy Chain immunolabeling — 8-weeks; Analysis of markers of neuromuscular junction integrity (NCAM biomarker staining) — 8-weeks; Changes in knee extension strength measured by a hand dynamometer — 8-weeks
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Urolithin A · 100%Title contains controlled term: urolithin a. Abstract contains controlled term: urolithin a. Source terminology contains: urolithin a. Title supplies longevity context: frail, older adult. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.